Journal article

Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis

Parinaz Mehdipour, Megha Rajasekhar, Saber Dini, Sophie Zaloumis, Tesfay Abreha, Ishag Adam, Ghulam Rahim Awab, J Kevin Baird, Larissa W Brasil, Cindy S Chu, Liwang Cui, Andre Daher, Margarete Gomes, Lilia Gonzalez-Ceron, Jimee Hwang, Harin Karunajeewa, Marcus VG Lacerda, Simone Ladeia-Andrade, Toby Leslie, Benedikt Ley Show all

Malaria Journal | BMC | Published : 2023

Abstract

Background: Imperfect adherence is a major barrier to effective primaquine radical cure of Plasmodium vivax. This study investigated the effect of reduced adherence on the risk of P. vivax recurrence. Methods: Efficacy studies of patients with uncomplicated P. vivax malaria, including a treatment arm with daily primaquine, published between January 1999 and March 2020 were identified. Individual patient data from eligible studies were pooled using standardized methodology. Adherence to primaquine was inferred from i) the percentage of supervised doses and ii) the total mg/kg dose received compared to the target total mg/kg dose per protocol. The effect of adherence to primaquine on the incid..

View full abstract

Grants

Awarded by Australian National Health and Medical Research Council (NHMRC)


Awarded by Wellcome Trust


Awarded by Australian NHMRC for the Australian Centre for Research Excellence in Malaria Elimination


Awarded by Bill & Melinda Gates Foundation


Awarded by Bill and Melinda Gates Foundation


Funding Acknowledgements

RJC, JAS and RNP are supported by Australian National Health and Medical Research Council (NHMRC) Investigator Grants (1194702, 1196068, 2008501). This work is supported by the Wellcome Trust (grant 089179 to CSC, FN and NJW ). NJW is a Wellcome Trust Principal Fellow (093956/Z/10/C). JH receives salary support from the U.S. President's Malaria Initiative. MVGL is a fellow from the National Council for Scientific and Technological Development (CNPq). This research was supported by a grant from Australian NHMRC for the Australian Centre for Research Excellence in Malaria Elimination (1134989). This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation INV-024389. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.